News | January 28, 2022
Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
The vaccines are currently only authorised for emergency use in the country
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Subscribe To Our Newsletter & Stay Updated
